SCHAUMBURG, Ill., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Propofol Injectable Emulsion USP 1%, in two Single-Dose, Single-Patient vial presentations of 20 mL and 100 mL. A 50 mL Single-Dose, Single-Patient vial presentation will be released shortly. According to IMS, for the 12 months ending September 2013, the US market for Propofol approximated $230 million.
"Sagent has a strong commitment to responding to our customers' needs by providing an extensive portfolio of injectable pharmaceutical products. One challenge many customers face is maintaining adequate supply of certain key products that are only available from a limited number of sources. Sagent has again fulfilled its commitment to our customers by becoming an alternative supplier of Propofol," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board of Sagent.
About Propofol Injectable Emulsion USP 1%
The package insert for Propofol Injectable Emulsion USP 1%, available at www.sagentpharma.com, contains the indications, complete side effect profile and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
Consistent with Sagent's position against the use of any of its products in connection with capital punishment, Sagent is taking appropriate steps to market Propofol only to healthcare facilities and to prevent the sale and delivery of this product to correctional facilities and prison systems.